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Too-Low Iron Doses and Too Many
Dropouts in Negative Iron Trial?
TO THE EDITOR:We read with interest the article by Steensma et
al1 in the January 1, 2011, issue of Journal of Clinical Oncology on the
comparison of parenteral, oral, or no iron supplementation for pa-
tients who were treated with darbepoetin alfa for chemotherapy-
associated anemia. The results contrast with those of six previously
published2-7 and two additionally reported8,9 clinical trials that showed a
significant benefit and good tolerability of parenteral iron compared
withoralorno ironsupplementation inpatientswithcancerwhowere
receiving a concomitant erythropoiesis-stimulating agent.We believe
that the interpretationandunderstandingof the results of the studyby
Steensma et al might have been facilitated by reporting some addi-
tional information. Both the lack of benefit and the higher number of
adverse events in the parenteral iron group may be related to the
specific dosing schedule of ferric gluconate in this trial (187.5 mg of
iron every 3 weeks).
The low planned total iron dose of 937.5 mg, the second lowest
dose among thepublished trials (750 to 3,000mg) and the lowest dose
when calculated on aweekly basis (62.5mg/wk),may have limited the
potential benefit of parenteral iron supplementation. Furthermore,
the iron dose that was actually administered seems to have been even
lower, namely 650mg total iron (43.3mg/wk), as indicated online by
Auerbach.10 In the study by Bastit et al4 that was cited by Steensma et
al1 as similar to their own study, the actually delivered total iron dose
was about 400 mg higher.10 The increase of transferrin saturation
(TSAT) from baseline to the end of the study that was reported by
Steensmaet alwas substantially lower in theparenteral iron compared
with the oral iron group, and even lower than in the placebo group
(1.4%, 8.0%, and 1.7%, respectively). This suggests that the
given total dose of parenteral ironwas either too low or not effectively
used. In this context, Steensma et al mention that patients who were
enrolled in the parenteral iron arm were more likely to withdraw
consent or discontinue treatment as a result of adverse events. No
information is given onhow this affected the number of administered
iron doses per patient.
In contrast to the low total iron dose throughout the entire study
period, the single iron doses administered per treatment as ferric
gluconate were rather high (187.5 mg) andmay explain the excessive
number of adverse events that led to early termination of the study. In
fact, this dose is 50% above the recommended dose for iron repletion
with ferric gluconate in adult patients receiving hemodialysis in the
United States, and therefore it is in the off-label range. Data from
Ferrlecit (sanofi-aventis, Bridgewater, NJ) postmarketing reports in-
dicate that individual doses that exceed 125mg of ironmay be associ-
ated with a higher incidence and/or severity of adverse events.11 The
high single doses of ferric gluconate in this studymay have resulted
in oversaturation of transferrin, formation of nontransferrin-
bound iron, and deposition of iron in parenchymal tissues (eg,
hepatocytes) instead of in the bone marrow. Apart from the in-
creased risk of inducing oxidative stress and thus causing associ-
ated adverse events, the described effects may have additionally
decreased the amount of iron that was effectively available for
erythropoiesis. Therefore, it would be relevant to knowmore about
the time course of TSAT and especially the levels of TSAT 24 hours
after ferric gluconate administration.
One aspect thatmay have affected the statistical power is the low
proportion of patients who completed the study per protocol (65%
overall; 63% in the placebo and the parenteral iron arm each). Thus,
given that more than one third of the patients did not complete the
study, a per-protocol analysis would be informative.
In summary, the lack of response to parenteral ferric glu-
conate in the study by Steensma et al1 may be attributed to a
suboptimal dosing regimen (ie, a low average dose but single doses
that were too high) and a high proportion of dropouts rather than
a lack of effectiveness per se. The superiority of parenteral iron
compared with oral or no iron supplementation in terms of better
hematopoietic response and less need for blood transfusions has
been confirmedby two recentmeta-analyses12,13 that includeddata
from this trial as presented by Steensma et al at the 2009meeting of
the American Society of Hematology.14
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